CN107001480B - 用于人c-maf的结合成员 - Google Patents

用于人c-maf的结合成员 Download PDF

Info

Publication number
CN107001480B
CN107001480B CN201580067068.4A CN201580067068A CN107001480B CN 107001480 B CN107001480 B CN 107001480B CN 201580067068 A CN201580067068 A CN 201580067068A CN 107001480 B CN107001480 B CN 107001480B
Authority
CN
China
Prior art keywords
antibody
maf
seq
ser
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580067068.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107001480A (zh
Inventor
R·戈米斯
J·C·特塞罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INBIOMOTION SL
Original Assignee
INBIOMOTION SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INBIOMOTION SL filed Critical INBIOMOTION SL
Publication of CN107001480A publication Critical patent/CN107001480A/zh
Application granted granted Critical
Publication of CN107001480B publication Critical patent/CN107001480B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580067068.4A 2014-12-11 2015-12-11 用于人c-maf的结合成员 Active CN107001480B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090599P 2014-12-11 2014-12-11
US62/090,599 2014-12-11
PCT/IB2015/059562 WO2016092524A1 (en) 2014-12-11 2015-12-11 Binding members for human c-maf

Publications (2)

Publication Number Publication Date
CN107001480A CN107001480A (zh) 2017-08-01
CN107001480B true CN107001480B (zh) 2021-12-03

Family

ID=55024191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580067068.4A Active CN107001480B (zh) 2014-12-11 2015-12-11 用于人c-maf的结合成员

Country Status (10)

Country Link
US (1) US10793642B2 (enExample)
EP (1) EP3229909B1 (enExample)
JP (1) JP2017538412A (enExample)
KR (1) KR20170093182A (enExample)
CN (1) CN107001480B (enExample)
AU (1) AU2015358868A1 (enExample)
BR (1) BR112017012515A2 (enExample)
CA (1) CA2967224C (enExample)
MX (1) MX2017007381A (enExample)
WO (1) WO2016092524A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (es) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
DK2906718T3 (da) 2012-10-12 2019-07-01 Inbiomotion Sl Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf
BR112015023510A2 (pt) 2013-03-15 2017-10-10 Fundacio Inst De Recerca Biomedica Irb Barcelona método para o diagnóstico, prognóstico e tratamento de câncer metastático
JP2017538412A (ja) 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． ヒトｃ−ｍａｆに対する結合メンバー
CN117230193A (zh) 2016-05-25 2023-12-15 生物运动有限公司 基于c-maf状态的乳腺癌治疗性治疗
EP3713581A1 (en) 2017-11-22 2020-09-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
PT1137941E (pt) 1998-12-10 2009-10-15 Brystol Myers Squibb Company Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação
HRP20010738B1 (en) 1999-03-15 2005-02-28 Axys Pharmaceuticals N-cyanomethyl amides as protease inhibitors
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
US20020009738A1 (en) 2000-04-03 2002-01-24 Houghton Raymond L. Methods, compositions and kits for the detection and monitoring of breast cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AU2002226390B2 (en) 2001-12-22 2007-11-15 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP3211086B1 (en) 2005-09-20 2021-06-09 Menarini Silicon Biosystems S.p.A. Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
AU2007269654B2 (en) 2006-06-30 2013-01-10 University Of Southern California Quantifiable internal reference standards for immunohistochemistry and uses thereof
WO2008086800A2 (en) 2007-01-15 2008-07-24 Aarhus Universitet Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
CN101772511A (zh) 2007-02-16 2010-07-07 太平洋艾瑞有限公司 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
RU2011101378A (ru) 2008-06-16 2012-07-27 Сайвидон Дайагностикс Гмбх (De) Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (es) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
DK2906718T3 (da) 2012-10-12 2019-07-01 Inbiomotion Sl Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
BR112015023510A2 (pt) 2013-03-15 2017-10-10 Fundacio Inst De Recerca Biomedica Irb Barcelona método para o diagnóstico, prognóstico e tratamento de câncer metastático
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
JP6550045B2 (ja) 2013-10-09 2019-07-24 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 乳がんに由来する骨の転移がんの予後診断および処置のための方法
JP2017538412A (ja) 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． ヒトｃ−ｍａｆに対する結合メンバー
CN117230193A (zh) 2016-05-25 2023-12-15 生物运动有限公司 基于c-maf状态的乳腺癌治疗性治疗
EP3713581A1 (en) 2017-11-22 2020-09-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf

Also Published As

Publication number Publication date
CA2967224C (en) 2023-08-22
US10793642B2 (en) 2020-10-06
KR20170093182A (ko) 2017-08-14
JP2017538412A (ja) 2017-12-28
EP3229909A1 (en) 2017-10-18
CN107001480A (zh) 2017-08-01
MX2017007381A (es) 2017-11-06
WO2016092524A1 (en) 2016-06-16
CA2967224A1 (en) 2016-06-16
EP3229909B1 (en) 2020-10-14
US20170369589A1 (en) 2017-12-28
AU2015358868A1 (en) 2017-06-01
BR112017012515A2 (pt) 2018-01-02

Similar Documents

Publication Publication Date Title
CN107001480B (zh) 用于人c-maf的结合成员
CN107667120B (zh) 抗muc16抗体及其应用
JP7032929B2 (ja) 抗ｐｄ－ｌ１抗体及びその診断上の使用
KR102571924B1 (ko) c-MAF 상태에 기초한 유방암의 치료
US20220315657A1 (en) Anti-pd-1 antibody for use in a method of treating a tumor
CN107098970B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
JP2020531045A (ja) 抗ｃｄ１６６抗体およびその使用
US9683032B2 (en) Anti-S100A4 antibody molecules and their uses
CA2919473A1 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
EP2743697B1 (en) Methods for the in vitro diagnosis of invasive carcinomas
CN111492246A (zh) 用于预测对napi2b靶向疗法的响应的组合物和方法
CN111565725A (zh) 基于c-maf状态的乳腺癌的治疗性处理
JP2024500512A (ja) 抗ｂ７－ｈ３抗体およびその使用
JP2020143122A (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
TWI716400B (zh) 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
WO2024254596A1 (en) Compositions and methods for detection of aberrant cdk5 expression
WO2020181080A1 (en) Biomarkers for treatment of cancer
HK40026235A (en) Therapeutic treatment of breast cancer based on c-maf status
HK40005535A (en) Plectin-1 binding antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant